Previous close | 13.65 |
Open | 14.00 |
Bid | 14.10 x 100 |
Ask | 14.25 x 200 |
Day's range | 14.00 - 14.20 |
52-week range | 6.70 - 18.00 |
Volume | |
Avg. volume | 302,345 |
Market cap | 3.959B |
Beta (5Y monthly) | 0.07 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.43 |
Earnings date | 21 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.50 |
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the developme
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term
REYKJAVIK, Iceland & PARSIPPANY, N.J., April 16, 2024--Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Under